AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease
AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the first patient in its pivotal phase 3 ... Read More
Feinstein Institute discovers potential of ACE inhibitors in preventing memory loss in lupus patients
New York-based Feinstein Institute for Medical Research finds that ACE inhibitors can prevent cognitive decline in lupus patients, according to a study published in the ... Read More